<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04453722</url>
  </required_header>
  <id_info>
    <org_study_id>20-505</org_study_id>
    <nct_id>NCT04453722</nct_id>
  </id_info>
  <brief_title>Prevention of Opioid-Induced Hypoxemia</brief_title>
  <official_title>Wearable Device for Prevention of Opioid-Induced Hypoxemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will evaluate the feasibility of a fully randomized validation trial for&#xD;
      the Oxalert EPO. All patients will wear the Oxalert for 24 hours preoperatively in the&#xD;
      monitoring only mode (no alerts), throughout hospitalization up to six days, and for 24&#xD;
      post-discharge hours. Randomization will be to Oxalert in monitor-only mode or to its normal&#xD;
      mode which provides progressive audible and tactile alerts for hypoxemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The fraction of time during the initial six post-operative in-hospital days that patients wear the device.</measure>
    <time_frame>initial six post-op in hospital days.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The frequency of hypoxemic episodes detected by the Oxalert EPO that generate an alert in the hospital.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted average SpO2 below a threshold of 90%.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of in-hospital postoperative desaturation events (saturation &lt;90%) lasting at least 2 min.</measure>
    <time_frame>6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of hypoxemic episodes (saturation &lt;90%) during the initial 24 post-discharge hours lasting at least 2 min.</measure>
    <time_frame>24 hours post discharge</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Oxalert in monitor only mode</arm_group_label>
    <description>Randomization will be to Oxalert in monitor-only mode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxalert in monitor in normal mode</arm_group_label>
    <description>Randomization will be to Oxalert in monitor normal mode which provides progressive audible and tactile alerts for hypoxemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxalert Monitor</intervention_name>
    <description>The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.</description>
    <arm_group_label>Oxalert in monitor only mode</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxalert Monitor</intervention_name>
    <description>The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode</description>
    <arm_group_label>Oxalert in monitor in normal mode</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will enroll patients who are at increased risk for respiratory&#xD;
        insufficiency. Specifically, the investigators will focus on patients scheduled for&#xD;
        laparoscopic or open major abdominal or pelvic surgery whose analgesia is primarily&#xD;
        opioid-based. The investigators will further restrict enrollment to obese patients (body&#xD;
        mass index kg/m2) who are likely to have respiratory compromise. Both men and women will be&#xD;
        recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults having major laparoscopic and open abdominal or pelvic surgeries;&#xD;
&#xD;
          -  Body Mass Index â‰¥25 kg/m2&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status 1-3;&#xD;
&#xD;
          -  Age 18-85 years old;&#xD;
&#xD;
          -  Able to understand and consent to the trial and fully participate;&#xD;
&#xD;
          -  Anticipated primary opioid analgesia after surgery;&#xD;
&#xD;
          -  Expected duration of hospitalization at least 24 hours after surgery;&#xD;
&#xD;
          -  Consenting at least 24 hours before anticipated surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Epidural analgesia (field and fascial plane blocks permitted);&#xD;
&#xD;
          -  Pre-operative SpO2 &lt;95%;&#xD;
&#xD;
          -  No wrist available for the study;&#xD;
&#xD;
          -  Severe hearing loss;&#xD;
&#xD;
          -  Lack of English language fluency.&#xD;
&#xD;
          -  Serious hearing deficit (unable to understand normal speech in a quite environment)&#xD;
&#xD;
          -  Serious peripheral neuropathy (unable to feel pin prick at wrist).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Sessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Johnson</last_name>
    <phone>216-444-9950</phone>
    <email>johnsor13@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Sessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

